World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
28043
World Ranking
16500
National Ranking
859

Michael Heuser publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael Heuser sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 574 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael Heuser D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Heuser sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael Heuser is affiliated with Hannover Medical School in Germany and has a substantial research portfolio primarily in the medical sciences. Their work focuses predominantly on hematology and molecular biology, with significant contributions spanning acute myeloid leukemia and related hematologic disorders.

Their main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology. Within these, subfields of research concentrate on hematology, molecular biology, genetics, public health, environmental and occupational health, and oncology.

Major topics covered in their research encompass:

  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Cancer Genomics and Diagnostics
  • Protein Degradation and Inhibitors
  • Multiple Myeloma Research and Treatments

Michael Heuser has published extensively in various scientific journals. Frequent publication venues include:

  • Blood
  • HemaSphere
  • Leukemia
  • Blood Advances
  • Clinical Lymphoma Myeloma & Leukemia

Among recent papers associated with or authored by Michael Heuser are:

  • 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), 2022, European Heart Journal
  • Molecular International Prognostic Scoring System for Myelodysplastic Syndromes, 2022, NEJM Evidence
  • 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party, 2021, Blood
  • Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes, 2020, Nature Medicine
  • 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), 2022, European Heart Journal - Cardiovascular Imaging

Michael Heuser collaborates regularly with several researchers who frequently co-author with them, including:

  • Felicitas Thol
  • Hartmut Döhner
  • Arnold Ganser
  • Konstanze Döhner
  • Walter Fiedler

Best Publications

  • Genomic Classification and Prognosis in Acute Myeloid Leukemia

    Elli Papaemmanuil;Moritz Gerstung;Lars Bullinger;Verena I Gaidzik

  • Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

    Gerrit J. Schuurhuis;Michael Heuser;Sylvie Freeman;Marie Christine Béne

  • Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

    Felicitas Thol;Sofia Kade;Carola Schlarmann;Patrick Löffeld

  • Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia

    Felicitas Thol;Frederik Damm;Andrea Lüdeking;Claudia Winschel

  • Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Elsa Bernard;Yasuhito Nannya;Robert P. Hasserjian;Sean M. Devlin

  • 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.

    Michael Heuser;Sylvie D Freeman;Gert J Ossenkoppele;Francesco Buccisano

  • Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

    Jorge E. Cortes;Florian H. Heidel;Andrzej Hellmann;Walter Fiedler

  • High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.

    Michael Heuser;Gernot Beutel;Juergen Krauter;Konstanze Döhner

  • Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes

    Felicitas Thol;Inna Friesen;Frederik Damm;Haiyang Yun

  • How I treat refractory and early relapsed acute myeloid leukemia.

    Felicitas Thol;Richard Friedrich Schlenk;Michael Heuser;Arnold Ganser

  • Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

    Katharina Wagner;Frederik Damm;Gudrun Göhring;Kerstin Görlich

  • Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

    Felicitas Thol;Razif Gabdoulline;Alessandro Liebich;Piroska Klement

  • RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

    V I Gaidzik;V Teleanu;E Papaemmanuil;D Weber

  • Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection.

    Sarina Ravens;Christian Schultze-Florey;Solaiman Raha;Inga Sandrock

  • Precision oncology for acute myeloid leukemia using a knowledge bank approach

    Moritz Gerstung;Moritz Gerstung;Elli Papaemmanuil;Elli Papaemmanuil;Inigo Martincorena;Lars Bullinger

  • Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

    Richard F. Schlenk;Richard F. Schlenk;Daniela Weber;Walter Fiedler;Helmut R. Salih

  • Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

    Anuhar Chaturvedi;Michelle Maria Araujo Cruz;Nidhi Jyotsana;Amit Sharma

  • IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

    Felicitas Thol;Eva M. Weissinger;Jürgen Krauter;Katharina Wagner

  • Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

    Felicitas Thol;Frederik Damm;Katharina Wagner;Gudrun Göhring

  • TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

    Detlef Haase;Kristen E Stevenson;Donna Neuberg;Jaroslaw P Maciejewski

Frequent Co-Authors

Arnold Ganser
Arnold Ganser Hannover Medical School
Konstanze Döhner
Konstanze Döhner University of Ulm
Hartmut Döhner
Hartmut Döhner University of Ulm
Richard F. Schlenk
Richard F. Schlenk University Hospital Heidelberg
Gudrun Göhring
Gudrun Göhring Hannover Medical School
Brigitte Schlegelberger
Brigitte Schlegelberger Hannover Medical School
Lars Bullinger
Lars Bullinger Charité - University Medicine Berlin
Michael Lübbert
Michael Lübbert University of Freiburg
Jorge E. Cortes
Jorge E. Cortes Augusta University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in a medical career but not pursuing a traditional MD, there are numerous accessible online pathways. Options such as online medical coding classes with financial aid can help learners launch a healthcare career without clinical requirements. These programs offer affordable and flexible entry into essential health services roles.

Aspiring nurses have opportunities as well; some lpn school without teas test options let you start nursing education without entrance exams, making the process less daunting.

Professionals seeking growth might pursue accelerated healthcare programs. These let you move quickly into management and administrative roles, addressing the ongoing need for healthcare leaders.

Finally, registered nurses can advance their careers and increase earning potential through adn to msn bridge programs. These flexible online options streamline the journey to advanced practice or education tracks.

Best Scientists Citing Michael Heuser

Trending Scientists

Recently Published Articles